<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055705</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000270801</org_study_id>
    <secondary_id>MSKCC-02080</secondary_id>
    <secondary_id>NCI-1617</secondary_id>
    <nct_id>NCT00055705</nct_id>
  </id_info>
  <brief_title>PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer</brief_title>
  <official_title>A Phase I Clinical Trial To Assess The Safety And Efficacy Of Intraperitoneal PV701 Administrations In Patients With Advanced Or Recurrent Malignancy Largely Confined To The Peritoneal Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have&#xD;
      advanced or recurrent ovarian epithelial, fallopian tube, primary peritoneal, colorectal, or&#xD;
      other cancer found primarily within the peritoneal cavity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of intraperitoneal PV701&#xD;
           after desensitization in patients with advanced or recurrent malignancy largely confined&#xD;
           to the peritoneal cavity these patients.&#xD;
&#xD;
        -  Determine the optimal desensitization dose of intravenous PV701 in these patients.&#xD;
&#xD;
        -  Determine the safety of this drug, in terms of cumulative toxicity, in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
        -  Determine the presence and duration of viral shedding, viremia, and immunogenicity of&#xD;
           this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study comprising 2 different treatment&#xD;
      schedules.&#xD;
&#xD;
        -  Schedule I (optimal desensitization dose): Patients receive PV701 IV over 30 minutes on&#xD;
           day 1 followed by intraperitoneal (IP) PV701 on days 4, 7, and 9. Courses repeat every&#xD;
           21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of PV701 IV and IP until the optimal&#xD;
      desensitization dose (ODD) is determined. The ODD is defined as the dose preceding that at&#xD;
      which at least 2 of 6 patients experience dose-limiting toxicity (DLT).&#xD;
&#xD;
        -  Schedule II (maximum tolerated dose):Patients receive the same regimen as in schedule I&#xD;
           using PV701 IV at the ODD.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of PV701 IP until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience DLT.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-50 patients will be accrued for this study within 10-17&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PV701</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histological confirmation of 1 of the following:&#xD;
&#xD;
               -  Ovarian epithelial carcinoma&#xD;
&#xD;
               -  Fallopian tube cancer&#xD;
&#xD;
               -  Primary peritoneal cancer&#xD;
&#xD;
               -  Advanced colorectal carcinoma&#xD;
&#xD;
               -  Other malignancy confined to the peritoneal cavity or peritoneal surfaces&#xD;
&#xD;
          -  No lesion greater than 2 cm in greatest diameter based on surgical re-assessment&#xD;
&#xD;
          -  Low burden of tumor in the abdominal or pelvic cavities and no clinically significant&#xD;
             ascites&#xD;
&#xD;
          -  Received potentially effective therapy when available (e.g., platinum/taxane for&#xD;
             ovarian cancer, fluoropyrimidine-based therapy for colorectal cancer)&#xD;
&#xD;
          -  No concurrent hematological malignancy (e.g., chronic lymphocytic leukemia or&#xD;
             non-Hodgkin's lymphoma)&#xD;
&#xD;
          -  No bilateral adrenal metastases&#xD;
&#xD;
          -  No adrenal metastases in the remaining adrenal gland after adrenalectomy (including&#xD;
             radical nephrectomy)&#xD;
&#xD;
          -  No lung tumors 5 cm or more&#xD;
&#xD;
          -  No pleural effusions (at least 25% of hemithorax) by radiography&#xD;
&#xD;
          -  No CNS metastases by CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 1.5 times ULN&#xD;
&#xD;
          -  No uncontrolled hepatic dysfunction&#xD;
&#xD;
          -  No active hepatitis B or C&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL AND/OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
          -  No uncontrolled renal dysfunction&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled cardiovascular dysfunction&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No life-threatening arrhythmias within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No uncontrolled pulmonary dysfunction&#xD;
&#xD;
          -  No pulmonary atelectasis (lobar)&#xD;
&#xD;
          -  No pulmonary infiltrates (lobar)&#xD;
&#xD;
          -  No pulmonary consolidation (lobar or segmental)&#xD;
&#xD;
          -  No baseline grade II dyspnea&#xD;
&#xD;
        Adrenal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No uncontrolled adrenal dysfunction&#xD;
&#xD;
          -  No known adrenal insufficiency&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled gastrointestinal dysfunction&#xD;
&#xD;
          -  No neurological dysfunction&#xD;
&#xD;
          -  No serious medical or psychological condition that would preclude study participation&#xD;
             or increase the risk of adverse effects of the study treatment&#xD;
&#xD;
          -  No history of serious immunodeficiency&#xD;
&#xD;
          -  No active uncontrolled bacterial infection (including asymptomatic urinary tract&#xD;
             infection)&#xD;
&#xD;
          -  No contraindication to intraperitoneal therapy including the following:&#xD;
&#xD;
               -  Intra-abdominal infection&#xD;
&#xD;
               -  Dense widespread adhesions&#xD;
&#xD;
               -  Peritonitis&#xD;
&#xD;
               -  Periumbilical infection&#xD;
&#xD;
               -  Bowel obstruction&#xD;
&#xD;
               -  Ileostomy&#xD;
&#xD;
          -  No hypersensitivity to eggs&#xD;
&#xD;
          -  No continued contact with live birds (e.g., poultry farmers, veterinarians, laboratory&#xD;
             technicians, pet store owners, breeders)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 3 prior cytotoxic chemotherapy regimens&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 14 days since prior systemic corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 30 days since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior complete or partial lobectomy with removal of lung tissue at least segmental&#xD;
             size&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 14 days since prior antiviral medication&#xD;
&#xD;
          -  More than 4 weeks since prior immunosuppressive drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent chronic immunosuppressive drugs (e.g., cyclosporine)&#xD;
&#xD;
          -  No vaccination for influenza within 48 hours of study drug administration&#xD;
&#xD;
          -  No concurrent hypoglycemic agents&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Spriggs, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2004</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>April 23, 2011</last_update_submitted>
  <last_update_submitted_qc>April 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>carcinoma of the appendix</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

